Home / Stocks / Epigral Limited
EPIGRAL

Epigral Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹945.1

Change

+0.8 (0.08%)

Open

₹933.5

Prev. Close

₹944.3

Day High

₹949.0

Day Low

₹933.5

Volume Analysis

Traded

9,934

Delivered

4,189

Delivery %

42.17%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (21.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹967.06 ₹958.03 ₹951.56 ₹942.53 ₹936.06 ₹927.03 ₹920.56
Fibonacci ₹958.03 ₹952.11 ₹948.45 ₹942.53 ₹936.61 ₹932.95 ₹927.03
Camarilla ₹949.36 ₹947.94 ₹946.52 ₹942.53 ₹943.68 ₹942.26 ₹940.84

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-25.15%

1 Week

+1.04%

1 Month

+0.54%

3 Months

-16.07%

6 Months

-24.46%

1 Year

-35.06%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹579.01

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

16.74%

Net margin 10.23% × asset turnover 0.48x × equity multiplier 3.41x

Company Overview

Sector

Chemicals

Market Cap

₹4,094 Cr

P/E (TTM)

14.4

ROE

16.0%

Book Value

₹548.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Epigral Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Chemicals sector, at 55/100. The strongest factor is Financial Strength (100/100), while Momentum (20/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%); promoter holding is falling.

TopFund Score — Fundamentals Quality

55/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

56

Valuation

52

Cash Flow

50

Corporate Governance

53

Momentum

20

Institutional Ownership

44

Business Quality

65

Risk & Volatility

28

Liquidity

27

From Screener.in

  • −Debtor days have increased from 42.4 to 60.2 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Epigral Limited submits Transcript of conference call held on Monday, 2nd November, 2026 discussing Q2 FY2027 Results.

Epigral Limited submits a copy of newspaper publication pertaining to Un-Audited Financial Results for Second quarter and hald year ended 30.09.2026

Epigral shared the audio recording of its Q2 FY27 results conference call.

Q2FY27 PAT rose 26% to ₹64 Cr; revenue up 28% to ₹752 Cr, with expansions nearing commissioning.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 478 472 525 651 626 645 628 607 587 597 736 705 746
Expenses + 370 349 369 475 448 463 454 443 455 494 569 526 610
Operating Profit 108 123 155 176 178 183 173 163 132 103 168 179 136
OPM % 23.0% 26.0% 30.0% 27.0% 28.0% 28.0% 28.0% 27.0% 22.0% 17.0% 23.0% 25.0% 18.0%
Other Income + 1 2 2 2 6 4 4 9 2 6 -1 5 6
Interest 21 20 14 14 27 0 12 23 22 11 16 7 11
Depreciation 32 31 30 33 32 33 34 42 42 43 42 43 44
Profit before tax 56 74 113 131 125 154 131 107 70 55 110 134 88
Tax % 32.0% 34.0% 32.0% 34.0% 35.0% 33.0% 34.0% -50.0% 26.0% 28.0% 26.0% 25.0% 26.0%
Net Profit + 38 49 77 86 81 104 87 161 51 39 81 100 65
EPS in Rs 9 12 19 21 20 24 20 37 12 9 19 23 15
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -14 -12 -7 43 31 37 20 -7 -6 -7 17 16 27

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 394 392 598 710 611 829 1,551 2,188 1,929 2,550 2,527 2,785
Expenses + 245 248 346 405 416 567 1,041 1,499 1,448 1,839 1,961 2,199
Operating Profit 149 144 252 306 194 261 509 689 481 711 566 586
OPM % 38.0% 37.0% 42.0% 43.0% 32.0% 32.0% 33.0% 31.0% 25.0% 28.0% 22.0% 21.0%
Other Income + 2 1 8 16 2 2 4 8 7 16 15 16
Interest 19 14 9 25 11 29 44 66 73 53 72 45
Depreciation 44 55 55 54 44 74 86 109 124 133 168 172
Profit before tax 88 75 195 242 141 161 383 522 291 541 341 385
Tax % 23.0% 11.0% 20.0% 25.0% 21.0% 37.0% 34.0% 32.0% 33.0% 34.0% 3.0% —
Net Profit + 67 67 155 183 112 101 253 353 196 358 332 285
EPS in Rs 9 9 22 44 27 24 61 85 47 83 77 66
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 6.0% 11.0% 7.0% 6.0% —
Sales growth — -1 52 19 -14 — 87 41 -12 32 -1 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 224 291 447 241 331 432 684 1,028 1,213 1,861 2,178 2,322
Borrowings + 190 123 74 601 737 753 993 879 964 593 572 570
Other Liabilities + 55 42 79 162 164 222 405 484 576 655 712 650
Total Liabilities 540 527 671 1,044 1,273 1,449 2,124 2,432 2,794 3,152 3,505 3,585
Fixed Assets + 364 398 347 295 440 1,102 1,068 1,804 1,767 2,238 2,117 2,061
CWIP 69 3 79 468 691 126 589 158 483 64 451 498
Investments 0 29 71 0 0 0 0 21 21 98 23 29
Other Assets + 106 98 173 281 142 221 467 450 524 752 915 997
Total Assets 540 527 671 1,044 1,273 1,449 2,124 2,432 2,794 3,152 3,505 3,585
Equity Capital 71 71 71 41 42 42 42 42 42 43 43 43

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + — — — — 165 229 284 626 398 441 436
Cash from Investing Activity + — — — — -363 -197 -455 -437 -401 -262 -355
Cash from Financing Activity + — — — — 69 -32 195 -200 -8 -164 -94
Net Cash Flow — — — — -129 1 24 -11 -11 15 -14
Free Cash Flow — — — — -205 32 -172 210 -1 254 50
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit — — — — 99 99 68 106 93 78 90

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 71.38% → 68.83%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 27.37% 27.1% 26.75% 25.12% 23.71% 23.34% 23.3% 23.52% 23.67% 24.71% 24.56% 25.27%
Promoters 71.38% 71.49% 71.58% 71.58% 68.94% 68.95% 68.83% 68.83% 68.83% 68.83% 68.83% 68.83%
Government 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%
FII 1.17% 1.36% 1.46% 2.1% 3.01% 3.01% 3.06% 2.71% 2.36% 1.54% 1.03% 0.99%
DII 0.05% 0.02% 0.18% 1.17% 4.31% 4.66% 4.78% 4.93% 5.13% 4.9% 5.56% 4.89%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Chemicals — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Epigral Limited (this stock) 4,094 14.4 1.73 16.0%
Steamhouse India Limited 4,178 96.0 7.22 25.3%
Dhanuka Agritech Ltd 4,010 13.3 2.28 20.5%
Laxmi Organic Indus Ltd 4,190 24.4 1.99 4.11%
Ghcl Limited 4,209 9.22 1.18 13.0%
Tatva Chin Pharm Chem Ltd 3,937 61.6 4.84 5.54%
Chemplast Sanmar Limited 3,888 — 2.46 -6.8%

Which Mutual Funds Hold Epigral Limited?

Frequently Asked Questions about Epigral Limited

Community Sentiment

What are other investors saying about Epigral Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.